Search Videos and More


New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life News

New Study Shows Young Women With Breast Cancer Who Opt for Mastectomies Report Lower Quality of Life

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber Brigham Cancer Center.
Newsweek Names Dana-Farber #3 in the World for Cancer News

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber Cancer Institute has been named one of the world’s very best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings.
Breast Cancer Research at ESMO Video

Breast Cancer Research at ESMO

Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
Dosing Strategies Help Personalize Care in HER2+ Breast Cancer News

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.
Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials Video

Updated Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Clinical Trials

Sara Tolaney, MD, MPH discusses updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0.
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch News

Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch

An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
Study of SACI-IO for Triple Negative Metastatic Breast Cancer Video

Study of SACI-IO for Triple Negative Metastatic Breast Cancer

Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer Video

Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer

Why test the combination of Trodelvy and pembrolizumab?
First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer News

First Mammography Screening Guidelines Issued for Older Survivors of Breast Cancer

A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening in survivors’ later years.